Traders should monitor for upcoming data readouts on preliminary efficacy and potential Phase IIb trial initiation. This success may attract investor interest or partnership deals, especially given the unmet need in AUD treatment.
Price Chart
Executive Summary
Clearmind Medicine announced that its drug candidate CMND-100 met the primary safety and tolerability endpoint in a Phase I/IIa clinical trial for Alcohol Use Disorder (AUD). The drug was well tolerated with no serious adverse events reported, supporting its advancement to later-stage trials.
Key Facts
- CMND-100 met the primary endpoint of safety and tolerability in a Phase I/IIa FDA-approved clinical trial for Alcohol Use Disorder.
- No serious adverse events were reported, even at higher dosages in the third cohort.
- The trial is multinational and multicenter, evaluating safety, tolerability, pharmacokinetics, and preliminary efficacy.
- CMND-100 is a non-hallucinogenic MEAI-based oral drug candidate.
Financial Impact
Positive catalyst for future funding and partnership opportunities; de-risks early-stage development risk.
Risk Factors
- Phase I/IIa results do not guarantee efficacy in larger trials.
- Future funding needs may lead to dilutive financing given the company's small market cap ($2M).
- Regulatory hurdles remain for full approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-043235 |
| Document: ea028625802ex99-1.htm | 0001213900-26-043235 |
| Document: 0001213900-26-043235-index-headers.html | 0001213900-26-043235 |
| Document: 0001213900-26-043235-index.html | 0001213900-26-043235 |
| Document: 0001213900-26-043235.txt | 0001213900-26-043235 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $5.92 | awaiting T+60 | — | $5.95 (+0.47%) |
Oct 27, 2026 today | Press Release | $6.50 | awaiting T+60 | — | $5.95 (−8.50%) |
Oct 16, 2026 10d ago | 6-K | $6.00 | awaiting T+60 | — | $5.95 (+0.87%) |
Oct 13, 2026 14d ago | 6-K | $6.23 | awaiting T+60 | — | $5.95 (−4.53%) |
Oct 8, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $5.95 (−9.88%) |
Oct 7, 2026 20d ago | 6-K | $6.60 | awaiting T+60 | — | $5.95 (−9.88%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $5.95 (+599.72%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $5.95 (+599.72%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $5.95 (−13.35%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $5.95 (+530.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers